PD-L1 monoanti-Bavencio: under review in Europe to treat metastatic urinary skin cancer

The European DrugAdministrationis reviewing Merck and Pfizer's PD-L1 monoanti-Bavencio (avelumab) for first-line maintenance treatment for patients with locally advanced or metastatic urinary skin cancer (UC)In the Eu, nearly 200,000 people are diagnosed with bladder cancer each year, and 60,000 of them die from the disease, underscoring the highly unmet needs of the disease90% of patients with bladder cancer are urethra cancer, which becomes more difficult to treat as the disease develops and may spread to all layers of the bladder wallAfter the transfer, the five-year survival rate of the disease is only 5%data from the JAVELIN Bladder 100 PHASE III study showed that Bavencio significantly improved the overall survival rate of patients with PD-L1-positive, untreated locally advanced or metastatic urinary path cancer (UC), thus offering hope for new first-line treatment options for this group of patientsin Europe, the drug has been approved for first-line treatment with axitinib for advanced renal cell carcinoma (RCC) in adults and as a single treatment for Merkel cell carcinoma